双胍类市场 - 按药物类型（品牌、仿製药）、剂型（片剂、口服溶液）、配方（速释、缓释）、配销通路（医院、零售、线上药局）、全球预测，2024 - 2032

由于全球第 2 型糖尿病 (T2DM) 盛行率不断上升，预计 2024 年至 2032 年双胍类市场规模的复合年增长率将达到 2.9%。根据世界卫生组织的数据，全球约有 4.22 亿人受到糖尿病影响，其中大多数居住在低收入和中等收入国家。生活方式的改变导致久坐的习惯和不良的饮食选择，导致糖尿病发病率不断上升。此外，不断扩大的老年人口，容易患上糖尿病等与年龄相关的疾病，也需要有效的管理策略，进一步刺激了对双胍疗法的需求。

药物研发的快速进步导致创新製剂和联合疗法的推出，以提高双胍的疗效和耐受性。这些进步迎合了不断变化的患者需求和偏好。此外，旨在提高糖尿病管理意识和提供负担得起的医疗保健解决方案的积极政府倡议将促进行业扩张。

双胍类药物产业分为药品种类、剂型、剂型、配销通路和区域。

按剂型划分，到 2032 年，仿製药市场规模预计将增长 3.4%。仿製药的可用性增加正在提高这种疗法的可及性，特别是在医疗资源有限或预算有限的地区。此外，仿製药经过严格的监管评估，以确保生物等效性和治疗功效，从而增强医疗保健专业人员和患者对其安全性和有效性的信心。

由于广泛的可近性和以患者为中心的服务，零售药房配销通路领域的双胍类市场预计在 2024 年和 2032 年期间复合年增长率为 3%。零售药局凭藉其广泛的网络和便利的地理位置，成为双胍药物的主要分销管道，确保了广泛的市场覆盖范围和患者的可用性。此外，零售药局透过向接受糖尿病管理处方疗法的个人提供有价值的咨询和支持服务，帮助患者教育和药物依从性。

在生活方式不断改变和人口老化的支持下，到 2032 年，欧洲双胍行业规模将以 3.1% 的复合年增长率大幅增长。旨在解决糖尿病盛行率和促进预防性医疗保健措施的积极政府措施将推动区域市场的成长。此外，欧洲国家强大的医疗基础设施和报销政策也促进了双胍疗法的获得。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 糖尿病盛行率上升
    • 高度偏好双胍类药物作为第一线治疗
    • 药物传输技术的进步
  • 产业陷阱与挑战
    • 与双胍类药物相关的副作用
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类型，2018 - 2032

• 主要趋势
• 品牌化
• 通用的

第 6 章：市场估计与预测：按剂型，2018 - 2032 年

• 主要趋势
• 平板电脑
• 口服溶液

第 7 章：市场估计与预测：按配方划分，2018 年 - 2032 年

• 主要趋势
• 立即发布
• 缓释

第 8 章：市场估计与预测：按配销通路，2018 年 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 10 章：公司简介

• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Cipla Ltd.
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals Ltd.
• Merck & Co., Inc.
• Sanofi
• Takeda Pharmaceutical Company Limited.
• Teva Pharmaceuticals Industries Ltd.
• Zydus Group

Biguanides Market size is expected to record 2.9% CAGR from 2024 to 2032, driven by the rising prevalence of type 2 diabetes mellitus (T2DM) globally. As per WHO, approximately 422 million individuals globally are affected by diabetes, with the majority residing in low- and middle-income nations. The influx of lifestyle changes leading to sedentary habits and poor dietary choices is contributing to the growing incidence of diabetes. Additionally, the expanding geriatric population, prone to age-related conditions, such as diabetes is also necessitating effective management strategies, further fueling the demand for biguanide-based therapies.

Rapid advancements in pharmaceutical R&D are leading to the introduction of innovative formulations and combination therapies for enhancing the efficacy and tolerability of biguanides. These advancements are catering to the evolving patient needs and preferences. Furthermore, proactive government initiatives aimed at raising awareness about diabetes management and providing affordable healthcare solutions will foster the industry expansion.

The biguanides industry is classified into drug type, dosage form, formulation, distribution channel and region.

By dosage form, the market size from the generic segment is poised to witness 3.4% growth rate through 2032. The expiration of patents on branded biguanide medications has led to the entry of generic alternatives for offering cost-effective treatment options for patients and healthcare providers. This increased availability of generic formulations is enhancing the accessibility to this therapy, particularly in regions with limited healthcare resources or budget constraints. Additionally, generic medications undergo stringent regulatory evaluations to ensure bioequivalence and therapeutic efficacy, instilling confidence among healthcare professionals and patients regarding their safety and efficacy.

Biguanides market from the retail pharmacies distribution channel segment is anticipated to observe a 3% CAGR during 2024 and 2032, owing to widespread accessibility and patient-centric service. With their extensive network and convenient locations, retail pharmacies serve as key distribution channels for biguanide medications, ensuring broad market reach and availability to patients. Furthermore, retail pharmacies help in patient education and medication adherence by providing valuable counseling and support services to individuals with prescribed therapies for diabetes management.

Europe biguanide industry size will grow significantly at 3.1% CAGR through 2032, backed by growing lifestyle changes and aging population. The proactive government initiatives aimed at addressing diabetes prevalence and promoting preventive healthcare measures will propel the regional market growth. Moreover, robust healthcare infrastructure and reimbursement policies in European countries are also facilitating access to biguanide therapies.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of diabetes
    • 3.2.1.2 High preference for biguanides as first line treatment
    • 3.2.1.3 Advancements in drug delivery technologies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects associated with biguanides
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Branded
• 5.3 Generic

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Tablets
• 6.3 Oral solutions

Chapter 7 Market Estimates and Forecast, By Formulation, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Immediate-release
• 7.3 Extended-release

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Boehringer Ingelheim International GmbH
• 10.2 Bristol-Myers Squibb Company
• 10.3 Cipla Ltd.
• 10.4 GlaxoSmithKline plc
• 10.5 Glenmark Pharmaceuticals Ltd.
• 10.6 Merck & Co., Inc.
• 10.7 Sanofi
• 10.8 Takeda Pharmaceutical Company Limited.
• 10.9 Teva Pharmaceuticals Industries Ltd.
• 10.10 Zydus Group